American College of Cardiology (ACC)

The American College of Cardiology (ACC) is the primary U.S. medical society representing the interests of all cardiology subspecialities. The ACC is very active in setting guidelines for cardiac care, lobbying for supportive government policy and reimbursements, clinician education, managing several key cardiovascular registries and advocating for the transformation of cardiovascular care to improve heart health.

PCI before TAVR? In older CAD patients, deferral may be the best approach
Patients with coronary artery disease and severe aortic stenosis often undergo PCI before TAVR. According to new data presented at ACC.26, however, deferring PCI is associated with comparable outcomes as well as a reduced bleeding risk.
Interventional cardiologist Roxana Mehran elected ACC president
A prominent figure in the fields of interventional cardiology and women’s health is now leading the American College of Cardiology.
New stroke prevention device for TAVR holds its own in head-to-head battle with Sentinel
A new embolic protection device from Emboline was noninferior to the FDA-approved Sentinel device in terms of safety and efficacy. In addition, it captured much more TAVR-generated debris and was linked to an improved technical success rate.
‘Practice-changing’ interventional cardiology research grabs ACC.26 spotlight
The second day of the American College of Cardiology’s annual conference started with a series of highly anticipated interventional cardiology trials.
Catheter-based treatment linked to major benefits for intermediate-risk PE
New 30-day data presented at ACC.26 helped answer questions cardiologists have had been asking for years. “Thank you for bringing PE into the future," one vascular specialist said from the stage.

Michiel Voskuil, MD, PhD, an interventional cardiologist and professor at University Medical Center Utrecht in the Netherlands, presented his team’s data on the ACC.26 stage.

PCI before TAVR? In older CAD patients, deferral may be the best approach

Patients with coronary artery disease and severe aortic stenosis often undergo PCI before TAVR. According to new data presented at ACC.26, however, deferring PCI is associated with comparable outcomes as well as a reduced bleeding risk.

Interventional cardiologist Roxana Mehran, MD, officially started her one-year term as the president of the American College of Cardiology (ACC) on the closing day of ACC.26, the group’s annual conference in New Orleans.

Interventional cardiologist Roxana Mehran elected ACC president

A prominent figure in the fields of interventional cardiology and women’s health is now leading the American College of Cardiology.

Adam Greenbaum, MD, presents late-breaking data at ACC.26.

New stroke prevention device for TAVR holds its own in head-to-head battle with Sentinel

A new embolic protection device from Emboline was noninferior to the FDA-approved Sentinel device in terms of safety and efficacy. In addition, it captured much more TAVR-generated debris and was linked to an improved technical success rate.

‘Practice-changing’ interventional cardiology research grabs ACC.26 spotlight

The second day of the American College of Cardiology’s annual conference started with a series of highly anticipated interventional cardiology trials.

Stavros V. Konstantinides, MD, PhD, presenting data at ACC.26

Catheter-based treatment linked to major benefits for intermediate-risk PE

New 30-day data presented at ACC.26 helped answer questions cardiologists have had been asking for years. “Thank you for bringing PE into the future," one vascular specialist said from the stage.

Cold weather responsible for many more stroke and heart attack deaths than heat

While heat consistently gets more attention in terms of public health messaging, new data show just how dangerous the cold can be.

Vascudyne's off-the-shelf conduit for CABG surgeries

New off-the-shelf conduit for CABG shows promise in first-in-human study

A new acellular tissue-engineered vessel developed by Vascudyne could provide surgeons with a safe, effective alternative to saphenous vein grafts.

Trends in telemedicine utilization from 2019-2024 for all Americans, Americans without atherosclerotic cardiovascular disease (ASCVD), and Americans With ASCVD.

How telehealth utilization among heart patients has evolved since the pandemic

The COVID-19 pandemic created a major shift in how telehealth services were being utilized. Those services were used much more often for some patient populations than others.